COVID-19 Induced Coagulopathy: A Common Challenge in Intensive Care Units
International Pharmacy Acta,
Vol. 8 No. 1 (2025),
6 Farvardin 2025
,
Page e9:1-6
https://doi.org/10.22037/ipa.v8i1.47874
Abstract
The ongoing Coronavirus disease (COVID-19) pandemic has caused widespread global transmission. Hemostatic disorders are known complications of the disease, leading to blood clots and bleeding. These disorders are associated with high mortality rates. This study aimed to determine the prevalence of hemostatic disorders among COVID-19 patients admitted to intensive care units (ICUs). During a one-year period, an observational cross-sectional study was conducted on COVID-19 patients admitted to Imam Khomeini Hospital in Ardabil. This study assessed 911 patients with COVID-19 who were hospitalized in the ICU, aged of 62.26 years on average, of which 54.3% were males. The mortality rate was 52.3% mortality rate. 8.6% of patients had thromboembolic or bleeding disorders. Most cases involved bleeding (5.9%), followed by DVT (2.1%) and PTE (0.8%). In our study, we found that patients with a history of thromboembolism (P-Value = 0.000), cancer (P-Value = 0.000), cardiovascular disease (P-Value = 0.025), hypertension (P-Value = 0.030), and rheumatological diseases (P-Value = 0.035) had significantly higher rates of thromboembolism and hemorrhagic events. The prevalence of thromboembolic and bleeding disorders was also significantly higher in patients with elevated LDH (0.001), INR (0.014), D-dimer (0.015), CRP (0.039), and BUN (0.046) levels. Our study elucidates three critical aspects of COVID-19-associated coagulopathy in patients admitted to the intensive care unit. The prevalence of hemostatic disorders was notably 8.6%, with bleeding complications being the most common at 5.9%. Significant associations were observed between thromboembolic events and pre-existing conditions, particularly prior thromboembolism and cancer. Laboratory markers, such as elevated levels of LDH, D-dimer, and INR, possess prognostic significance for identifying patients at high risk.
- Hemorrhage
- Hemostatic disorders
- Intensive care unit
- Pulmonary embolism
- SARS-CoV-2 infection
- Venous thrombosis
How to Cite
References
1. Noor FM, Islam MM. Prevalence and associated risk factors of mortality among COVID-19 patients: a meta-analysis. Journal of community health. 2020;45(6):1270-1282.
2. [Gulen M, Satar S. Uncommon presentation of COVID-19: Gastrointestinal bleeding. Clinics and Research in Hepatology and Gastroenterology. 2020;44(4):e72-e76.
3. Boregowda U, Aloysius MM, Perisetti A, et al. Serum activity of liver enzymes is associated with higher mortality in COVID-19: a systematic review and meta-analysis. Frontiers in medicine. 2020;7:431.
4. Hanff TC, Mohareb AM, Giri J, et al. Thrombosis in COVID‐19. American journal of hematology. 2020;95(12):1578-1589.
5. Aliasgarzade S, Matin S, Javaheri N, et al. Coagulation disorders in hospitalized COVID-19 patients and relationship with disease outcome: A cross-sectional study. Archives of Clinical Infectious Diseases. 2021;16(5).
6. Aliasgarzadeh S, Arabzadeh A, Fathibitaraf S, Negaresh M. Sudden development of the upper and lower limb ischemia as the first manifestation of COVID-19 infection. International Journal of Surgery Case Reports. 2022;96:107332.
7. Chen G, Wu D, Guo W, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. The Journal of clinical investigation. 2020;130(5):2620-2629.
8. Henry BM, De Oliveira MHS, Benoit S, et al. Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis. Clinical Chemistry and Laboratory Medicine (CCLM). 2020;58(7):1021-1028.
9. Ranucci M, Ballotta A, Di Dedda U, et al. The procoagulant pattern of patients with COVID‐19 acute respiratory distress syndrome. Journal of thrombosis and haemostasis. 2020;18(7):1747-1751.
10. Giannis D, Ziogas IA, Gianni P. Coagulation disorders in coronavirus infected patients: COVID-19, SARS-CoV-1, MERS-CoV and lessons from the past. Journal of Clinical Virology. 2020;127:104362.
11. England JT, Abdulla A, Biggs CM, et al. Weathering the COVID-19 storm: lessons from hematologic cytokine syndromes. Blood Reviews. 2021;45:100707.
12. Al-Samkari H, Gupta S, Leaf RK, et al. Thrombosis, bleeding, and the observational effect of early therapeutic anticoagulation on survival in critically ill patients with COVID-19. Annals of internal medicine. 2021;174(5):622-632.
13. Jenner WJ, Kanji R, Mirsadraee S, et al. Thrombotic complications in 2928 patients with COVID-19 treated in intensive care: a systematic review. Journal of thrombosis and thrombolysis. 2021;51:595-607.
14. Tamayo-Velasco Á, Bombín-Canal C, Cebeira MJ, et al. Full Characterization of thrombotic events in all hospitalized COVID-19 patients in a Spanish tertiary hospital during the first 18 months of the pandemic. Journal of Clinical Medicine. 2022;11(12):3443.
15. Mohamud MFY, Mukhtar MS. Epidemiological characteristics, clinical relevance, and risk factors of thromboembolic complications among patients with COVID-19 pneumonia at A teaching hospital: Retrospective observational study. Annals of Medicine and Surgery. 2022;77:103660.
16. Xiong X, Chi J, Gao Q. Prevalence and risk factors of thrombotic events on patients with COVID-19: a systematic review and meta‐analysis. Thrombosis journal. 2021;19(1):32.
17. Khan IH, Savarimuthu S, Leung MST, Harky A. The need to manage the risk of thromboembolism in COVID-19 patients. Journal of vascular surgery. 2020;72(3):799-804.
18. Chen S, Zhang D, Zheng T, et al. DVT incidence and risk factors in critically ill patients with COVID-19. Journal of Thrombosis and Thrombolysis. 2021;51:33-39.
19. Abdelaal A, Abu-Elfatth A, Bakkar LM, et al. Assessment of COVID-19 associated coagulopathy and multiple hemostatic markers: a single center study in Egypt. Infection. 2023;51(3):655-664.
20. Prince MR, Dev H, Lane EG, et al. Major hemorrhage and mortality in COVID-19 patients on therapeutic anticoagulation for venous thromboembolism. Journal of Thrombosis and Thrombolysis. 2022;54(3):431-437.
21. Voicu S, Bonnin P, Stépanian A, et al. High prevalence of deep vein thrombosis in mechanically ventilated COVID-19 patients. Journal of the American College of Cardiology. 2020;76(4):480-482.
22. Thondapu V, Montes D, Rosovsky R, et al. Venous thrombosis, thromboembolism, biomarkers of inflammation, and coagulation in coronavirus disease 2019. Journal of Vascular Surgery: Venous and Lymphatic Disorders. 2021;9(4):835-844. e4.
23. Zinellu A, Paliogiannis P, Carru C, Mangoni AA. INR and COVID-19 severity and mortality: a systematic review with meta-analysis and meta-regression. Advances in medical sciences. 2021;66(2):372-380.
- Abstract Viewed: 101 times
- IPA-2025 Vol8i1-e9 Downloaded: 35 times